McKesson Corporation (MCK)
McKesson to acquire controlling stake in Core Ventures for $2.49 billion in cash
McKesson Corp. MCK, -1.56% said Monday it has agreed to acquire a controlling stake in Community Oncology Revitalization Enterprise Ventures, LLC , or Core Ventures, a physician-owned community oncology practice to about $2.49 billion in cash. Once the deal closes, Core Ventures will become part of McKesson's oncology network.
McKesson (MCK) Stock Gains 18% YTD: What's Driving the Rally?
McKesson's (MCK) shares rally on the back of solid fundamentals. Increasing volumes of prescription and specialty drugs boost the top line.
McKesson Corporation (MCK) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to McKesson (MCK). This makes it worthwhile to examine what the stock has in store.
McKesson Revenue Hurt by Supply and Demand Issues for Weight-Loss Drugs
McKesson (MCK) shares tumbled Thursday, a day after the healthcare services provider warned that limited supply of GLP-1 weight-loss drugs is hurting sales.
McKesson (MCK) Q1 Earnings Beat Estimates, Revenues Up Y/Y
McKesson's (MCK) first-quarter fiscal 2025 results showcase growth in the U.S. Pharmaceutical segment. However, Medical Surgical Solutions suffers due to lower COVID-related sales.
McKesson Reports Weak Sales, Joins JFrog, Fastly, Warner Bros. Discovery And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Dow futures falling around 0.2% on Thursday.
McKesson (MCK) Reports Q1 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for McKesson (MCK) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
McKesson (MCK) Tops Q1 Earnings Estimates
McKesson (MCK) came out with quarterly earnings of $7.88 per share, beating the Zacks Consensus Estimate of $7.16 per share. This compares to earnings of $7.27 per share a year ago.
McKesson misses quarterly revenue as U.S. pharmaceutical segment weighs
McKesson Corp reported weaker-than-expected first-quarter revenue on Wednesday due to soft demand for branded and specialty drugs that dragged sales down in its U.S. pharmaceuticals segment.
3 Healthcare Stocks Positioned for Possible Market Outperformance
So far in 2024, healthcare stocks have run into periodic earnings challenges compared to historical first quarters. For example, quarterly earnings for healthcare stocks across the board were down 25% compared to first-quarter 2023 earnings.
Here's Why McKesson (MCK) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Should You Buy, Sell or Hold McKesson (MCK) Before Q1 Earnings?
McKesson's (MCK) first-quarter fiscal 2025 results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment, driven by higher prescription volume.
